Search clinical trials for: Fluticasone Propionate/Formoterol Fumarate

Total 737 results

SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
Dey

Completed

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Asthma

United States, Canada
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Asthma

United States, Canada
Dey

Completed

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Terminated

Study of Safety of Foradil in Patients With Persistent Asthma

Persistent Asthma

United States
Mundipharma Research Limited

Completed

Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma (FLT2503)

Asthma

Germany
Mundipharma Research Limited

Completed

Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

Asthma Bronchiale

United Kingdom
SkyePharma AG
Abbott

Completed

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

Mild to Moderate Asthma

United States
SkyePharma AG

Completed

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients

Asthma

United Kingdom, Ireland
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Asthma

United Kingdom, Germany, Hungary, Poland, Romania
Mundipharma Research Limited

Completed

Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma

Asthma

Romania, Hungary, Czechia, France, Germany, Poland
Dey

Completed

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Mundipharma Research Limited

Completed

A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers

Asthma

United Kingdom
SkyePharma AG
Abbott

Completed

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

Asthma

United States, Ukraine, Mexico, Peru, Romania
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Chiesi Farmaceutici S.p.A.

Completed

EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI

Bronchial Asthma

Poland, Ukraine
AstraZeneca
Parexel

Completed

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Chronic Obstructive Pulmonary Disease - COPD

United States
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
Consorzio Futuro in Ricerca

Completed

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (PMC-101-APT)

Asthma | COPD

Italy
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management (QvarAsthma)

Asthma

United Kingdom
University of Florida
Food and Drug Administration (FDA)

Completed

Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution

Asthma

United States
University Medical Center Groningen

Unknown

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

COPD

Netherlands
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Asthma

Japan
Chiesi Farmaceutici S.p.A.

Completed

Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

Asthmatic

United Kingdom
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Asthma, Allergic

China
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom
Dey

Completed

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

Healthy

United States
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
Research in Real-Life Ltd
Napp Pharmaceuticals Limited

Completed

A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

Asthma

United Kingdom
GlaxoSmithKline

Completed

Fluticasone Nasal Spray Patient Preference Study

Rhinitis, Allergic, Perennial

United States
Mundipharma Research Limited

Terminated

A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)

Slovakia
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
AstraZeneca

Terminated

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
National Jewish Health

Completed

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Asthma

United States
Mundipharma Research Limited

Completed

A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma

Asthma

United Kingdom, Sweden, Australia, New Zealand, Slovakia
University of California, Los Angeles
Dey, L.P.

Withdrawn

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)

Chronic Obstructive Pulmonary Disease | Emphysema | COPD | Chronic Bronchitis

United States
AstraZeneca

Completed

Atlantis Symbicort

Asthma
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (EXPEDITION)

Asthma

Denmark, United States, Canada, Germany, Sweden, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

Asthma

United Kingdom
AstraZeneca

Completed

Symbicort Onset of Action 1

Asthma
GlaxoSmithKline

Completed

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Asthma

Germany, France
Sunovion

Completed

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
AstraZeneca

Completed

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom
Imperial College London

Completed

Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate

Healthy | Asthma

United Kingdom
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
Organon and Co

Completed

Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)

Asthma
Mundipharma Korea Ltd

Terminated

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol (RECONFFIRM)

Asthma
Teva Pharmaceuticals USA

Terminated

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Seasonal Allergic Rhinitis

United States

3

Subscribe